$901 Million is the total value of GREAT POINT PARTNERS LLC's 31 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AKBA | Exit | AKEBIA THERAPEUTICS INC | $0 | – | -131,531 | -100.0% | -0.11% | – |
NVAX | Exit | NOVAVAX INCput | $0 | – | -2,000,000 | -100.0% | -0.11% | – |
SLDB | Exit | SOLID BIOSCIENCES INCcall | $0 | – | -200,000 | -100.0% | -0.18% | – |
NVAX | Exit | NOVAVAX INCcall | $0 | – | -4,500,000 | -100.0% | -0.24% | – |
SVRA | Exit | SAVARA INC | $0 | – | -660,366 | -100.0% | -0.48% | – |
ARRY | Exit | ARRAY BIOPHARMA INCcall | $0 | – | -200,000 | -100.0% | -0.48% | – |
DERM | Exit | DERMIRA INCput | $0 | – | -555,300 | -100.0% | -0.74% | – |
CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -959,077 | -100.0% | -1.02% | – |
FGEN | Exit | FIBROGEN INCput | $0 | – | -200,000 | -100.0% | -1.08% | – |
CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -998,841 | -100.0% | -1.31% | – |
KRYS | Exit | KRYSTAL BIOTECH INC | $0 | – | -492,100 | -100.0% | -1.60% | – |
ASND | Exit | ASCENDIS PHARMA ASput | $0 | – | -200,000 | -100.0% | -2.33% | – |
EPZM | Exit | EPIZYME INC | $0 | – | -2,173,913 | -100.0% | -2.67% | – |
PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -900,000 | -100.0% | -3.46% | – |
ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -1,800,000 | -100.0% | -4.34% | – |
UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -379,832 | -100.0% | -4.41% | – |
ICPT | Exit | INTERCEPT PHARMACEUTICALS INCput | $0 | – | -400,000 | -100.0% | -4.43% | – |
BCRX | Exit | BIOCRYST PHARMACEUTICALS | $0 | – | -5,955,762 | -100.0% | -4.80% | – |
GBT | Exit | GLOBAL BLOOD THERAPEUTICS INC | $0 | – | -1,180,000 | -100.0% | -6.18% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.